Literature DB >> 15106296

Circulating vaccine-derived polioviruses: current state of knowledge.

Olen M Kew1, Peter F Wright, Vadim I Agol, Francis Delpeyroux, Hiroyuki Shimizu, Neal Nathanson, Mark A Pallansch.   

Abstract

Within the past 4 years, poliomyelitis outbreaks associated with circulating vaccine-derived polioviruses (cVDPVs) have occurred in Hispaniola (2000-01), the Philippines (2001), and Madagascar (2001-02). Retrospective studies have also detected the circulation of endemic cVDPV in Egypt (1988-93) and the likely localized spread of oral poliovirus vaccine (OPV)-derived virus in Belarus (1965-66). Gaps in OPV coverage and the previous eradication of the corresponding serotype of indigenous wild poliovirus were the critical risk factors for all cVDPV outbreaks. The cVDPV outbreaks were stopped by mass immunization campaigns using OPV. To increase sensitivity for detecting vaccine-derived polioviruses (VDPVs), in 2001 the Global Polio Laboratory Network implemented additional testing requirements for all poliovirus isolates under investigation. This approach quickly led to the recognition of the Philippines and Madagascar cVDPV outbreaks, but of no other current outbreaks. The potential risk of cVDPV emergence has increased dramatically in recent years as wild poliovirus circulation has ceased in most of the world. The risk appears highest for the type 2 OPV strain because of its greater tendency to spread to contacts. The emergence of cVDPVs underscores the critical importance of eliminating the last pockets of wild poliovirus circulation, maintaining universally high levels of polio vaccine coverage, stopping OPV use as soon as it is safely possible to do so, and continuing sensitive poliovirus surveillance into the foreseeable future. Particular attention must be given to areas where the risks for wild poliovirus circulation have been highest, and where the highest rates of polio vaccine coverage must be maintained to suppress cVDPV emergence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15106296      PMCID: PMC2585883     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  59 in total

1.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

2.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Isolation of vaccine-derived polioviruses in the Slovak Republic.

Authors:  B Cernáková; Z Sobotová; I Rovný; S Bláhova; M Roivainen; T Hovi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

Review 4.  Poliomyelitis and the postpolio syndrome.

Authors:  Robin S Howard
Journal:  BMJ       Date:  2005-06-04

5.  Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.

Authors:  E A Cherkasova; M L Yakovenko; G V Rezapkin; E A Korotkova; O E Ivanova; T P Eremeeva; L I Krasnoproshina; N I Romanenkova; N R Rozaeva; L Sirota; V I Agol; K M Chumakov
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay.

Authors:  Devasena Gnanashanmugam; Meira S Falkovitz-Halpern; Anthony Dodge; Melanie Fang; Lisa J Wong; Melissa Esparza; Rebecca Hammon; Enrique E Rivas-Merelles; Jose I Santos; Yvonne Maldonado
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

7.  Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, Argentina.

Authors:  Judith E Mueller; Maël Bessaud; Q Sue Huang; Laura C Martinez; Patricia A Barril; Viviane Morel; Jean Balanant; Judy Bocacao; Joanne Hewitt; Brad D Gessner; Francis Delpeyroux; Silvia V Nates
Journal:  Appl Environ Microbiol       Date:  2009-01-05       Impact factor: 4.792

8.  The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens
Journal:  Medscape J Med       Date:  2008-08-13

9.  Limited and localized outbreak of newly emergent type 2 vaccine-derived poliovirus in Sichuan, China.

Authors:  Dongmei Yan; Yong Zhang; Shuangli Zhu; Na Chen; Xiaolei Li; Dongyan Wang; Xiaozhen Ma; Hui Zhu; Wenbin Tong; Wenbo Xu
Journal:  Clin Vaccine Immunol       Date:  2014-05-21

10.  Impact of exogenous sequences on the characteristics of an epidemic type 2 recombinant vaccine-derived poliovirus.

Authors:  Franck B Riquet; Claire Blanchard; Sophie Jegouic; Jean Balanant; Sophie Guillot; Marie-Anne Vibet; Mala Rakoto-Andrianarivelo; Francis Delpeyroux
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.